Korro Bio, Inc. (KRRO)
(Real Time Quote from BATS)
$47.48 USD
-1.67 (-3.40%)
Updated Jul 15, 2024 11:14 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
KRRO 47.48 -1.67(-3.40%)
Will KRRO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for KRRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KRRO
Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade
Best Momentum Stocks to Buy for February 16th
KRRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for February 16th
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
Other News for KRRO
KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023
Korro Bio’s Chief Scientific Officer Announces Resignation
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), AbbVie (ABBV) and Emergent Biosolutions (EBS)
option delistings on June 3rd
Korro to Participate in Upcoming June Investor and Scientific Conferences